Technical Analysis for HRTX - Heron Therapeutics, Inc.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Strong | Down | Down | Flat |
| See historical HRTX trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Wide Bands | Range Expansion | 0.00% | |
| Wide Bands | Range Expansion | -1.38% | |
| 1,2,3 Retracement Bearish | Bearish Swing Setup | -2.52% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -2.52% | |
| MACD Bullish Signal Line Cross | Bullish | -2.52% | |
| Wide Bands | Range Expansion | -2.52% | |
| Up 3 Days in a Row | Strength | -2.52% | |
| Inside Day | Range Contraction | -1.77% | |
| Wide Bands | Range Expansion | -1.77% | |
| Wide Bands | Range Expansion | -1.71% |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/09/2019
- Sector: Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
Heron Therapeutics, Inc., a specialty pharmaceutical company, develops product candidates using its proprietary Biochronomer polymer-based drug delivery platform. The company's drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by converting them from products that should be injected once or twice per day to products that need to be injected once every one or two weeks. Its lead product candidate, Sustol, is developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting for patients undergoing emetogenic chemotherapy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Redwood City, California.
Medicine Health Pharmaceutical Clinical Medicine Oncology Chemotherapy Cancer Treatments Antineoplastic Drugs Occupational Safety And Health Drug Delivery Injectable Pharmaceuticals
Medicine Health Pharmaceutical Clinical Medicine Oncology Chemotherapy Cancer Treatments Antineoplastic Drugs Occupational Safety And Health Drug Delivery Injectable Pharmaceuticals
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more HRTX news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 42.9 |
| 52 Week Low | 16.2 |
| Average Volume | 1,344,295 |
| 200-Day Moving Average | 27.9665 |
| 50-Day Moving Average | 22.4566 |
| 20-Day Moving Average | 19.413 |
| 10-Day Moving Average | 17.806 |
| Average True Range | 1.0323 |
| ADX | 40.22 |
| +DI | 16.6666 |
| -DI | 34.214 |
| Chandelier Exit (Long, 3 ATRs ) | 21.4631 |
| Chandelier Exit (Short, 3 ATRs ) | 19.2969 |
| Upper Bollinger Band | 24.6937 |
| Lower Bollinger Band | 14.1323 |
| Percent B (%b) | 0.35 |
| BandWidth | 54.40375 |
| MACD Line | -1.5305 |
| MACD Signal Line | -1.6587 |
| MACD Histogram | 0.1282 |
| Fundamentals | Value |
|---|---|
| Market Cap | 964.19 Million |
| Num Shares | 54.1 Million |
| EPS | -4.15 |
| Price-to-Earnings (P/E) Ratio | -4.29 |
| Price-to-Sales | 59.70 |
| Price-to-Book | 11.60 |
| PEG Ratio | -0.17 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 18.71 | ||||
| Resistance 3 (R3) | 18.72 | 18.43 | 18.56 | ||
| Resistance 2 (R2) | 18.43 | 18.20 | 18.43 | 18.51 | |
| Resistance 1 (R1) | 18.12 | 18.06 | 17.98 | 18.11 | 18.46 |
| Pivot Point | 17.83 | 17.83 | 17.76 | 17.83 | 17.83 |
| Support 1 (S1) | 17.52 | 17.60 | 17.38 | 17.51 | 17.16 |
| Support 2 (S2) | 17.23 | 17.46 | 17.23 | 17.11 | |
| Support 3 (S3) | 16.92 | 17.23 | 17.06 | ||
| Support 4 (S4) | 16.91 |
